Common Clinical and Molecular Pathways between Migraine and Sarcoidosis
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24098304 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Claudio Tana und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence on Headache, Geriatrics and COVID-19 Clinic, SS Annunziata Hospital of Chieti, 66100 Chieti, Italy. Hauptthemen laut MEDLINE: Sarcoidosis, Central Nervous System Diseases, Migraine Disorders. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Migraine and sarcoidosis are two distinct medical conditions that may have some common biological and clinical pathways. Sarcoidosis is a chronic granulomatous disease characterized by the formation of granulomas in various organs, including the lungs, skin, cardiovascular system, lymph nodes, and brain. Migraine is a common comorbidity in sarcoidosis patients and a common neurological disorder characterized by recurrent headaches that can be accompanied by other symptoms, such as nausea, vomiting, and sensitivity to light and sound. There have been several reports of individuals with neurosarcoidosis experiencing migraines, though the exact relationship between the two disorders is not well understood. Both conditions have been associated with inflammation and the activation of the immune system. In sarcoidosis, the formation of granulomas is thought to be an immune response to the presence of an unknown antigen. Similarly, the pain and other symptoms associated with migraines are thought to be caused by inflammation in the brain and the surrounding blood vessels. There is also evidence to suggest an interplay of environmental and genetic factors playing a role in both conditions, but evidence is inconsistent with the hypothesis of shared genetic susceptibility. This review aims to illustrate common clinical and biological pathways between migraine and sarcoidosis, including inflammation and dysregulation of the immune system, with a focus on the cumulative burden of concurrent disorders and therapeutic implications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center of Excellence on Headache, Geriatrics and COVID-19 Clinic, SS Annunziata Hospital of Chieti, 66100 Chieti, Italy.
- Headache Unit, Department of Neurology, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain.
- Rare Diseases Referral Center, Internal Medicine 1, Ca' Foncello Hospital-AULSS2 Marca Trevigiana and Department of Medicine-DIMED, University of Padova, 35122 Padova, Italy.
- Department of Neuroscience, Imaging and Clinical Sciences, "G. D'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
- 2nd Internal Medicine Unit, SS. Medical Department, SS. Annunziata Hospital of Chieti, 66100 Chieti, Italy.
- University Cardiology Division, Heart Department, SS. Annunziata Hospital of Chieti, 66100 Chieti, Italy.
ORCID-Profile: David Garcia Azorin, Marco Tana, Fabrizio Ricci, Paolo Martelletti
Zitieren
APA
Tana, C., Azorin, D. G., Cinetto, F., Mantini, C., Tana, M., Caulo, M., Ricci, F., Martelletti, P., Cipollone, F., & Giamberardino, M. A. (2023). Common Clinical and Molecular Pathways between Migraine and Sarcoidosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24098304
Vancouver
Tana C, Azorin DG, Cinetto F, Mantini C, Tana M, Caulo M, et al. Common Clinical and Molecular Pathways between Migraine and Sarcoidosis. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24098304
BibTeX
@article{Tana2023,
author = {Tana, Claudio and Azorin, David Garcia and Cinetto, Francesco and Mantini, Cesare and Tana, Marco and Caulo, Massimo and Ricci, Fabrizio and Martelletti, Paolo and Cipollone, Francesco and Giamberardino, Maria Adele},
title = {Common Clinical and Molecular Pathways between Migraine and Sarcoidosis},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24098304}
}
EUVIMED